Cost-effectiveness Analysis of Lorlatinib in Patients Previously Treated with Anaplastic Lymphoma Kinase Inhibitors for Non-small Cell Lung Cancer in Greece | Published in Journal of Health Economics and Outcomes Research

Loading [Contrib]/a11y/accessibility-menu.js

Metrics
Cost-effectiveness Analysis of Lorlatinib in Patients Previously Treated with Anaplastic Lymphoma Kinase Inhibitors for Non-small Cell Lung Cancer in Greece

George Gourzoulidis, Oresteia Zisimopoulou, Nadia Boubouchairopoulou, Christina Michailidi, Chrissy Lowry, Charalampos Tzanetakos, Georgia Kourlaba,

cost-effectivenesslorlatinibanaplastic lymphoma kinaseGreecenon-small cell lung cancer

• https://doi.org/10.36469/jheor.2022.32983

Pageviews and PDF downloads

Pageviews Downloads

0 past 90 days

Last 7 days Last 30 days Last 90 days All time

No results for selected time period